28637-61-8Relevant academic research and scientific papers
Reaction of isatoic anhydride with bifunctional reagents: Synthesis of some new quinazolone fused heterocycles, 2-substituted anilinoheterocyclic derivatives and other related compounds
Fadda,Refat,Zaki,Monir
, p. 3537 - 3545 (2001)
A new synthesis of quinazolone fused heterocycles (2, 5, 8), anilinoheterocycles (4, 7, 10, 12, 14) and substituted 2-aminoquinoline (15, 16) based on the reaction of isatoic anhydride (1) with different active bifunctional compounds in presence of glacial acetic acid and freshly fused sodium acetate is described. Structures of the newly prepared compounds are established by chemical and spectral data.
Synthesis and palladium(II) metal chemistry of thiazoline/imidazoline derived ligands: An efficient catalyst for cross-coupling reactions of arylboronic acids with acid chlorides and aryl halides
Sudharsan, Murugesan,Suresh
, p. 598 - 608 (2018/09/18)
The synthesis, reactivity, spectroscopic characterization and catalytic activities of a series of Pd(II) complexes bearing the chelating ligands 2-(4,5-dihydrothiazol-2-yl)aniline (2) and 2-(4,5-dihydro-1H-imidazol-2-yl)aniline (3) are reported. The reactions of 2 with [Pd(COD)Cl2] in 1:1 and 1:2 (ligand into metal and metal into ligand) molar ratios afforded the mononuclear complexes, PdCl2{κ2?N,S ? 2?(4,5-dihydrothiazol-2-yl)aniline} (4), Pd{κ2?N,N’?2?(4,5-dihydrothiazol-2-yl)aniline}2 (5) and Pd{κ12?N,N’?κ22?N,S ? 2?(4,5-dihydrothiazol-2-yl)aniline}2 (6), respectively, in good yields. The neutral mononuclear palladium complexes PdCl2{κ2?N,N’?(4,5-dihydro-1H-imidazol-2-yl)aniline} (7) and Pd{κ2?N,N’?2?(4,5-dihydro-1H-imidazol-2-yl)aniline}2 (8) were synthesized using [Pd(COD)Cl2] with appropriate molar ratios. The palladium complexes 4–8 were evaluated for their catalytic activities in base assisted cross coupling reactions between acid chlorides and aryl halide with boronic acids. The complex 4 was found to be an efficient catalyst for producing unsymmetrical ketones (TOF = 19.8 min?1) while complex 7 was effective for making biaryls (TOF = 19.8 min?1).
IRIDIUM COMPLEX COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME
-
Paragraph 0075-0078, (2018/06/09)
The present invention relates to an iridium complex compound and an organic electroluminescent device using the same. More specifically, the present invention relates to an iridium complex compound securing low driving voltage as well as excellent color purity, luminescent properties, luminescent efficiency, and lifespan properties when used as a dopant in light-emitting layers of organic electroluminescent devices by producing the novel compound which is a complex having iridium as central metal. The present invention further relates to a method for efficiently synthesizing the same, and an organic electroluminescent device using the same.(01) Substrate(02) Positive electrode(03) Negative electrode(04) Hole injection layer(05) Hole transporting layer(06) Light-emitting layer(07) Electron transporting layer(08) Electron injection layerCOPYRIGHT KIPO 2018
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)
Scott, William J.,Hentemann, Martin F.,Rowley, R. Bruce,Bull, Cathy O.,Jenkins, Susan,Bullion, Ann M.,Johnson, Jeffrey,Redman, Anikó,Robbins, Arthur H.,Esler, William,Fracasso, R. Paul,Garrison, Timothy,Hamilton, Mark,Michels, Martin,Wood, Jill E.,Wilkie, Dean P.,Xiao, Hong,Levy, Joan,Stasik, Enrico,Liu, Ningshu,Schaefer, Martina,Brands, Michael,Lefranc, Julien
, p. 1517 - 1530 (2016/08/27)
The phosphoinositide 3-kinase (PI3K) pathway is aberrantly activated in many disease states, including tumor cells, either by growth factor receptor tyrosine kinases or by the genetic mutation and amplification of key pathway components. A variety of PI3K isoforms play differential roles in cancers. As such, the development of PI3K inhibitors from novel compound classes should lead to differential pharmacological and pharmacokinetic profiles and allow exploration in various indications, combinations, and dosing regimens. A screening effort aimed at the identification of PI3Kγ inhibitors for the treatment of inflammatory diseases led to the discovery of the novel 2,3-dihydroimidazo[1,2-c]quinazoline class of PI3K inhibitors. A subsequent lead optimization program targeting cancer therapy focused on inhibition of PI3Kα and PI3Kβ. Herein, initial structure–activity relationship findings for this class and the optimization that led to the identification of copanlisib (BAY 80-6946) as a clinical candidate for the treatment of solid and hematological tumors are described.
An expedient synthesis of 5-substituted imidazo[1,2-c]quinazolines
Korshin, Edward E.,Sabirova, Leila A.,Levin, Yakov A.
, p. 3512 - 3522 (2013/01/15)
An efficient three-step synthesis of 5-substituted 2,3-dihydroimidazo[1,2- c]quinazolines and imidazo[1,2-c]quinazolines was elaborated. 2-(2-Aminophenyl)-4,5-dihydro-1H-imidazole, prepared by phosphorus pentasulfide catalyzed condensation of 2-aminobenzonitrile with ethylenediamine, smoothly reacted with aldehydes to give the corresponding 2,3,5,6-tetrahydroimidazo[1,2- c]quinazolines. The CH-NH fragments of the latter were subjected to selective oxidative dehydrogenation with one equivalent of potassium permanganate on silica gel to give 2,3-dihydroimidazo[1,2-c]quinazolines. With two equivalents of potassium permanganate on silica gel, a one-pot exhaustive dehydrogenation to imidazo[1,2-c]quinazolines was accomplished. Georg Thieme Verlag KG · Stuttgart · New York.
FUSED AZOLE-PYRIMIDINE DERIVATIVES
-
Page 107, (2008/06/13)
The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidy
Synthesis, evaluation and structure-activity relationships of 5-alkyl-2,3-dihydroimidazo [1,2-c] quinazoline, 2,3 dihydroimidazo [1,2-c] quinazolin-5 (6H) thiones and their oxo-analogues as new potential bronchodilators
Bahekar,Rao
, p. 284 - 292 (2007/10/03)
With an aim to obtain potent bronchodilators, two series of 5-alkyl-2,3-dihydroimidazo [1,2-c] quinazolines (Va-1), 2,3-dihydroimidazo [1,2-c] quinazolin-5-(6H)-thiones (VIIIa-d) and their oxo-analogues (IXa-d) have been designed. The compounds Va-1 were synthesized by two alternative routes. The former (Method A) based on the dehydrocyclization of 4-(1-hydroxyethyl)-aminoquinazoline (IV) and the latter (Method B) involves the usage of 2-aminobenzonitrile (VI) which on reaction with ethylenediamine leads to the formation of the key intermediate 2-(2-aminophenyl)-4,5-dihydro-1H-imidazoles (VII). Finally the intermediate VII on condensation with different acidanhydrides yielded the title compound V. In general method-A resulted the compound V in quantatively higher yields. 2,3-Dihydroimidazo[1,2-c]quinazolin-5 (6H)-thiones (VIII) were obtained by condensing VII with carbon disulfide and a further oxidation of VIII responding oxo-analogues (IX). The title compounds V, VIII and IX were evaluated for their bronchodilator activity using in vitro and in vivo (standard animal models) methods, All the test compounds exhibited bronchodilatory activity. The structure activity relationship studies indicated good correlation between the nature of the substituent and bronchodilatory activity. In the 5-alkyl substituted compounds V, a longer alkyl chain showed higher bronchodilatory activity. Compounds VIII and IX were found to be less potent and replacement of sulphur with oxygen showed no significant effect on the biological activity. The presence of halogens altered the biological activity in both the series. Among the compounds tested, 9-iodo-5-(n-propyl)-2,3-dihydroimidazo[1,2-c]qulnazoline (VI) was found to be the most potent (percentage protection = 87.1%; relative activity = 1.1 compared to the standard aminophylline).
An Activated Trifluoromethyl Group as a New Synthon for 4,5-Dihydro-1H-imidazole and 1,4,5,6-Tetrahydropyrimidine Systems
Wydra, Roman L.,Patterson, Steven E.,Strekowski, Lucjan
, p. 803 - 805 (2007/10/02)
Treatment of 4-(trifluoromethyl)benzenamine 1a and 2-(trifluoromethyl)benzenamine 1b with lithium 2-aminoethylamide gives 2-(4-aminophenyl)-4,5-dihydro-1H-imidazole 3a and 2-(2-aminophenyl)-4,5-dihydro-1H-imidazole 3b, respectively.Similar reactions of 1a
